Genomic Health Inc. (NASDAQ:GHDX)’s share price traded up 1.2% during mid-day trading on Wednesday . The company traded as high as $26.49 and last traded at $26.47, with a volume of 55,111 shares changing hands. The stock had previously closed at $26.16.

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and issued a $38.00 price objective on shares of Genomic Health in a research note on Friday, August 5th. Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the company a “sell” rating in a research note on Wednesday, August 3rd. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, August 4th. Jefferies Group increased their target price on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Finally, Leerink Swann reiterated a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Genomic Health presently has a consensus rating of “Hold” and an average price target of $32.44.

The firm’s 50 day moving average is $27.81 and its 200-day moving average is $26.57. The company’s market capitalization is $889.34 million.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). During the same period last year, the firm earned ($0.29) earnings per share. The company had revenue of $81.97 million for the quarter, compared to the consensus estimate of $81.27 million. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. On average, equities analysts forecast that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

In other news, insider James J. Vaughn sold 1,997 shares of the business’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $28.00, for a total value of $55,916.00. Following the completion of the sale, the insider now owns 34,076 shares of the company’s stock, valued at $954,128. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $28.87, for a total transaction of $144,350.00. Following the completion of the sale, the chief operating officer now directly owns 40,426 shares of the company’s stock, valued at approximately $1,167,098.62. The disclosure for this sale can be found here.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.